

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Pemigatinib (Pemazyre)

Notes:

- Quantity Limits: Yes

Initiation (new start) criteria: Non-formulary **pemigatinib (Pemazyre)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Patient is at least 18 years of age
- Diagnosis of unresectable, locally advanced, or metastatic cholangiosarcoma
- Prior treatment with a first-line chemotherapy regimen per National Comprehensive Cancer Network (NCCN) Hepatobiliary Cancers Guideline (e.g. gemcitabine+cisplatin/oxaliplatin, 5-FU/capecitabine+cisplatin/oxaliplatin, gemcitabine+nab-paclitaxel, gemcitabine+capecitabine, gemcitabine+nab-paclitaxel+cisplatin, 5-FU, capecitabine, gemcitabine, pembrolizumab, entrectinib, larotrectinib) per NCCN Biliary Tract Cancers Guidelines
- Patient has fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **pemigatinib (Pemazyre)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Patient is at least 18 years of age
- Diagnosis of unresectable, locally advanced or metastatic cholangiosarcoma
- Fibroblast growth factor receptor 2 (FGFR2) genetic alteration fusion or rearrangement

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Pemigatinib (Pemazyre)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary pemigatinib (Pemazyre) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Patient is at least 18 years of age
- Diagnosis of unresectable, locally advanced or metastatic cholangiosarcoma
- Fibroblast growth factor receptor 2 (FGFR2) genetic alteration fusion or rearrangement

kp.org

Revised: 05/13/21
Effective: 07/15/21

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest